Xófigo vs 177Lu-labelled anti-PSMA

Introduction - PCa (Prostate Cancer) is a disease with a high incidence rate. Xofigo (223Ra dichloride) is a medicine indicated for patients with this disease in the metastatic phase specifically, symptomatic bone metastases. 177Lu-anti-PSMA represents a set of promising molecules in radioimmunother...

Full description

Bibliographic Details
Main Author: Agostinho, Daniela (author)
Other Authors: Costa, Melissa (author), Galaio, Salomé (author)
Format: conferenceObject
Language:eng
Published: 2017
Subjects:
Prostate cancer
Xofigo
Metastatic phase
177Lu-anti-PSMA
Online Access:http://hdl.handle.net/10400.21/7789
Country:Portugal
Oai:oai:repositorio.ipl.pt:10400.21/7789

Internet

http://hdl.handle.net/10400.21/7789

Similar Items